Search Results
Treatment approaches for patients with TP53m AML ineligible for high intensity chemotherapy
Challenges in Treating TP53-Mutated AML, Hope on the Horizon
What Is Low-Intensity AML Therapy?
Challenges in treating patients with TP53-mutated AML and future outlooks
High-grade vs low-grade chemotherapy in patients with relapsed AML or MDS
Treatment options for patients with TP53-mutated AML
Lower-intensity frontline therapy for newly diagnosed AML
Tolerability and efficacy of magrolimab plus azacitidine in TP53-mutated AML patients
The challenges of treating TP53-mutated AML and MDS
The benefit of allogeneic transplantation in patients with TP53-mutated AML
Magrolimab in TP53-mutated AML and MDS: What are the latest updates from EHA2022?
Is TP53-mutated high-risk MDS the same disease as TP53-mutated AML?
